Erratum to: Alzheimer disease and cancer risk: a meta-analysis [J Cancer Res Clin Oncol, DOI 10.1007/s00432-014-1773-5];Alzheimer disease and cancer risk: a meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 3, 2015, Pages 485-494

  Shi, Hai bin ^a   Tang, Bo ^a   Liu, Yao Wen ^a   Wang, Xue Feng ^a   Chen, Guo Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Meta analysis; Neoplasms; Risk

Indexed keywords

ALZHEIMER DISEASE; COHORT ANALYSIS; HUMAN; META ANALYSIS; NEOPLASMS; PATHOPHYSIOLOGY; PROGNOSIS;

ALZHEIMER DISEASE; COHORT STUDIES; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 84928213932     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1811-3     Document Type: Erratum

References (59)

1. Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166(4):367–378. doi:10.1093/aje/kwm116
2. Bajaj A, Driver JA, Schernhammer ES (2010) Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21(5):697–707. doi:10.1007/s10552-009-9497-6
3. Baker FM, Jordan B, Barclay L, Schoenberg BS (1993) Risk factors for clinically diagnosed Alzheimer’s disease. Int J Geriatr Psychiatry 8(5):379–385
4. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
5. Behrens MI, Lendon C, Roe CM (2009) A common biological mechanism in cancer and Alzheimer’s disease? Curr Alzheimer Res 6(3):196–204
6. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z (2011) Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer (Oxford Engl 1990) 47(13):1928–1937. doi:10.1016/j.ejca.2011.03.003
7. Chen RJ, Ho YS, Guo HR, Wang YJ (2008) Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci Off J Soc Toxicol 104(2):283–293. doi:10.1093/toxsci/kfn086
8. Dash SK (2013) Cognitive impairment and diabetes. Recent Pat Endocr Metab Immune Drug Discov 7(2):155–165
9. DePinho RA (2000) The age of cancer. Nature 408(6809):248–254. doi:10.1038/35041694
10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
11. Driver JA (2012) Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 3(1):58–67. doi:10.1016/j.jgo.2011.11.007
12. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP, Seshadri S, Wolf PA (2012) Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ Clin Res Ed 344:e1442. doi:10.1136/bmj.e1442
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ Clin Res Ed 315(7109):629–634
14. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159. doi:10.1056/NEJMra072067
15. Galliot B, Tanaka E, Simon A (2008) Regeneration and tissue repair: themes and variations. Cell Mol Life Sci 65(1):3–7. doi:10.1007/s00018-007-7424-0
16. Ganguli M, Dodge HH (2006) Mortality and survival in Alzheimer’s disease: a 15-year community study. Res Pract Alzheimer’s Dis 11:277–283
17. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (2005) Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 62(5):779–784
18. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135(11):1301–1309
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ Clin Res Ed 327(7414):557–560. doi:10.1136/bmj.327.7414.557
20. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR (2013) Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case–control analysis. Epilepsia 54(4):700–707. doi:10.1111/epi.12045
21. Jagger C, Clarke M, Stone A (1995) Predictors of survival with Alzheimer’s disease: a community-based study. Psychol Med 25(1):171–177
22. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32(4–5):577–595. doi:10.1007/s11064-006-9128-5
23. Jorm AF, Jolley D (1998) The incidence of dementia—a meta-analysis. Neurology 51(3):728–733
24. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ (1991) Clinical risk-factors for Alzheimers-disease—a population-based case–control study. Neurology 41(9):1393–1397
25. Lau JK, Brown KC, Thornhill BA, Crabtree CM, Dom AM, Witte TR, Hardman WE, McNees CA, Stover CA, Carpenter AB, Luo H, Chen YC, Shiflett BS, Dasgupta P (2013) Inhibition of cholinergic signaling causes apoptosis in human bronchioalveolar carcinoma. Cancer Res 73(4):1328–1339. doi:10.1158/0008-5472.can-12-3190
26. Lee CH, Huang CS, Chen CS, Tu SH, Wang YJ, Chang YJ, Tam KW, Wei PL, Cheng TC, Chu JS, Chen LC, Wu CH, Ho YS (2010) Overexpression and activation of the alpha9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J Natl Cancer Inst 102(17):1322–1335. doi:10.1093/jnci/djq300
27. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, Price DL, Eberhart CG, Wong PC (2007) Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci Off J Soc Neurosci 27(40):10849–10859. doi:10.1523/jneurosci.2152-07.2007
28. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R (2000) Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology 54(4):833–837
29. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD (2009) Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer’s disease. PLoS One 4(8):e6617. doi:10.1371/journal.pone.0006617
30. Mehler MF (2008) Epigenetics and the nervous system. Ann Neurol 64(6):602–617. doi:10.1002/ana.21595
31. Migliore L, Coppede F (2002) Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 512(2–3):135–153
32. Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C, Palmer K, Russo A (2013) Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology 81(4):322–328. doi:10.1212/WNL.0b013e31829c5ec1
33. Nery AA, Resende RR, Martins AH, Trujillo CA, Eterovic VA, Ulrich H (2010) Alpha 7 nicotinic acetylcholine receptor expression and activity during neuronal differentiation of PC12 pheochromocytoma cells. J Mol Neurosci 41(3):329–339. doi:10.1007/s12031-010-9369-2
34. Nordberg A (1994) Human nicotinic receptors—their role in aging and dementia. Neurochem Int 25(1):93–97
35. Ou SM, Lee YJ, Hu YW, Liu CJ, Chen TJ, Fuh JL, Wang SJ (2013) Does Alzheimer’s disease protect against cancers? A nationwide population-based study. Neuroepidemiology 40(1):42–49. doi:10.1159/000341411
36. Paradise M, Walker Z, Cooper C, Blizard R, Regan C, Katona C, Livingston G (2009) Prediction of survival in Alzheimer’s disease—the LASER-AD longitudinal study. Int J Geriatr Psychiatry 24(7):739–747. doi:10.1002/gps.2190
37. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6(12):e1001257. doi:10.1371/journal.pgen.1001257
38. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D (2011) The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 22(5):646–659. doi:10.1097/EDE.0b013e31822708b5
39. Realmuto S, Cinturino A, Arnao V, Mazzola MA, Cupidi C, Aridon P, Ragonese P, Savettieri G, D’Amelio M (2012) Tumor diagnosis preceding Alzheimer’s disease onset: is there a link between cancer and Alzheimer’s disease? J Alzheimer’s Dis 31(1):177–182. doi:10.3233/jad-2012-120184
40. Roe CM, Behrens MI (2013) AD and cancer: epidemiology makes for strange bedfellows. Neurology 81(4):310–311. doi:10.1212/WNL.0b013e31829c5f16
41. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC (2005) Alzheimer disease and cancer. Neurology 64(5):895–898. doi:10.1212/01.wnl.0000152889.94785.51
42. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R, Behrens MI, Morris JC (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74(2):106–112. doi:10.1212/WNL.0b013e3181c91873
43. Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 9(3):195–205. doi:10.1038/nrc2590
44. Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. doi:10.1007/s10654-010-9491-z
45. Staropoli JF (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays News Rev Mol Cell Dev Biol 30(8):719–727. doi:10.1002/bies.20784
46. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 283(15):2008–2012
47. Takahashi K, Uchida C, Shin RW, Shimazaki K, Uchida T (2008) Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer’s disease. Cell Mol Life Sci 65(3):359–375. doi:10.1007/s00018-007-7270-0
48. The Health Consequences of Smoking: A Report of the Surgeon General (2004). Atlanta GA
49. Tsai PH, Chen SP, Lin KN, Wang PN, Wang HC, Liu CY, Hong CJ, Liu HC (2007) Survival of ethnic Chinese with Alzheimer’s disease: a 5-year longitudinal study in Taiwan. J Geriatr Psychiatry Neurol 20(3):172–177. doi:10.1177/0891988707301864
50. Ubhi K, Masliah E (2013) Alzheimer’s disease: recent advances and future perspectives. J Alzheimer’s Dis 33(Suppl 1):S185–S194. doi:10.3233/jad-2012-129028
51. van Dijk PT, Dippel DW, Habbema JD (1991) Survival of patients with dementia. J Am Geriatr Soc 39(6):603–610
52. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8(4):275–283. doi:10.1038/nrm2147
53. Walker A (1991) Observation and Inference: An introduction to the methods of epidemiology. Epidemiology Resources Inc, Newton Lower Falls
54. Warpman U, Nordberg A (1995) Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6(17):2419–2423
55. Wevers A, Schroder H (1999) Nicotinic acetylcholine receptors in Alzheimer’s disease. J Alzheimer’s Dis 1(4–5):207–219
56. White RS, Lipton RB, Hall CB, Steinerman JR (2013) Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. Neurology 80(21):1966–1972. doi:10.1212/WNL.0b013e3182941990
57. Wu CH, Lee CH, Ho YS (2011) Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res 17(11):3533–3541. doi:10.1158/1078-0432.ccr-10-2434
58. Zanetti O, Solerte SB, Cantoni F (2009) Life expectancy in Alzheimer’s disease (AD). Arch Gerontol Geriatr 49(Suppl 1):237–243. doi:10.1016/j.archger.2009.09.035
59. Zhao Y, Shen L, Ji HF (2012) Alzheimer’s disease and risk of hip fracture: a meta-analysis study. Sci World J 2012:872173. doi:10.1100/2012/872173